Diagnostic accuracy of loop-mediated isothermal amplification as a near-patient test for meningococcal disease in children: An observational cohort study by Bourke, Thomas et al.
Diagnostic accuracy of loop-mediated isothermal amplification
as a near-patient test for meningococcal disease in children: An
observational cohort study
Bourke, T. W., McKenna, J. P., Coyle, P. V., Shields, M. D., & Fairley, D. J. (2015). Diagnostic accuracy of loop-
mediated isothermal amplification as a near-patient test for meningococcal disease in children: An observational
cohort study. The Lancet Infectious Diseases, 15(5), 552-558. DOI: 10.1016/S1473-3099(15)70038-1
Published in:
The Lancet Infectious Diseases
Document Version:
Early version, also known as pre-print
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
© 2015 the author(s)
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:15. Feb. 2017
	 1
Diagnostic accuracy of ‘loop mediated isothermal amplification’ (LAMP) as a near-1	
patient test for meningococcal disease in children 2	
 3	
Thomas W. Bourke MD a,c  4	
James P. McKenna PhD b  5	
Prof Peter V. Coyle MD b  6	
Prof Michael D. Shields MD a,c  7	
Derek J. Fairley PhD a,b  8	
 9	
a Centre for Infection and Immunity, Queen’s University Belfast, Belfast, UK 10	
b Regional Virus Laboratory, Department of Microbiology, Belfast Health & Social Care 11	
Trust, Belfast, UK 12	
c Royal Belfast Hospital for Sick Children, Belfast Health & Social Care Trust, Belfast, 13	
UK  14	
 15	
Address correspondence to: 16	
 17	
Professor Michael D. Shields, 18	
Centre for Infection & Immunity, 19	
Health Sciences Building, 20	
97 Lisburn Road, Belfast, BT9 7AE, UK 21	
Email:  m.shields@qub.ac.uk  22	
 23	
  24	
	 2
Abstract 25	
 26	
Background: Diagnosis of meningococcal disease relies on recognition of clinical signs and 27	
symptoms that are notoriously non-specific, variable, and often absent in the early stages of 28	
disease. Laboratory testing serves primarily to confirm the clinical diagnosis, as results may 29	
not be available for many hours or days. A method called ‘loop mediated isothermal 30	
amplification’ (LAMP) has previously been shown to be fast and effective for molecular 31	
detection of meningococcal DNA in clinical specimens. 32	
Methods: We evaluated the diagnostic accuracy (sensitivity and specificity) of 33	
meningococcal LAMP as a near-patient test in the emergency department of a large 34	
children’s hospital. Respiratory (nasopharyngeal swab) and blood specimens from children 35	
with suspected meningococcal infection were tested using a near-patient LAMP protocol 36	
and compared to reference laboratory testing. 37	
Findings: Combined testing of respiratory and blood specimens using LAMP was accurate 38	
(sensitivity 89%; specificity 100%; PPV 100%; NPV 98%) and diagnostically useful 39	
(positive and negative likelihood ratios of ∞ and 0.11 respectively). The median time 40	
required for near-patient testing was 1 hour 26 minutes from sample to result. 41	
Interpretation: Meningococcal LAMP is simple enough for use in any hospital with basic 42	
laboratory facilities, and near-patient testing using this method is both feasible and effective. 43	
In contrast to current UK NICE guidance, we found molecular testing of non-invasive 44	
respiratory specimens from children to be diagnostically accurate and clinically useful. 45	
Funding: Health & Social Care Research and Development, Public Health Agency, Northern 46	
Ireland. 47	
  48	
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Introduction 49	
 50	
Clinical diagnosis is the current standard for identifying invasive Neisseria meningitidis 51	
infection (meningococcal disease, MD) despite the signs and symptoms being notoriously 52	
non-specific, especially in young children.1,2 Although MD can progress very quickly, the 53	
typical signs and symptoms (if present) do not appear until a median of 13 to 22 hours after 54	
the first onset of symptoms, and half of children who present to their GP in the early stages 55	
of MD are not referred or admitted to hospital at the first presentation.3 Conversely, fear of 56	
missing the diagnosis also leads to overtreatment.4 Most children admitted and treated as 57	
suspected MD turn out to have a less serious infection, and a previous study in our hospital 58	
found two thirds of children treated as possible MD had an alternative diagnosis.5 Although 59	
introduction of an effective vaccine against serogroup B meningococcus should reduce the 60	
prevalence of meningococcal infection,6 there is considerable scope to improve diagnostic 61	
testing. 62	
 63	
Laboratory tests serve only to confirm the clinical diagnosis, as definitive results are rarely 64	
available in time to influence clinical decision making.7 We previously developed a rapid 65	
and effective molecular test based on ‘loop-mediated isothermal amplification’ (LAMP) to 66	
detect meningococcal DNA (ctrA gene) in clinical specimens.8 This assay gives equivalent 67	
performance to the current UK reference molecular test (TaqMan® real-time PCR9–12) but is 68	
faster and less expensive. In the UK, the National Institute of Health and Care Excellence 69	
(NICE) recognises that molecular (PCR) testing of sterile site specimens for meningococcus 70	
is very effective, but also notes that PCR is not available in most hospitals due to resource 71	
limitations.13  72	
 73	
	 4
Detection of meningococcal DNA in a sterile site (blood or CSF) specimen confirms a 74	
diagnosis of invasive MD,13 but this testing assumes that a level of clinical suspicion is 75	
already present. Collecting blood or CSF specimens from every patient with pyrexia but 76	
without the classical features of meningococcal infection is neither feasible nor desirable. 77	
Nevertheless, this group will include the small number of patients who have early-stage MD 78	
and who are at risk of being falsely reassured. Obtaining a nasopharyngeal specimen is 79	
relatively non-invasive, although current advice in the UK is not to test these for 80	
meningococcus due to the risk of detecting asymptomatic carriage.13 We have previously 81	
shown, using sensitive and specific PCR methods, that carriage rates of pathogenic 82	
(capsular) meningococci in young children are very low.14 Our previous study found 83	
molecular testing of throat swabs had a sensitivity of 81% and a specificity of 100% for 84	
diagnosis of MD. If a suitable molecular assay to detect capsular meningococci is used, we 85	
propose that near-patient testing of non-invasive respiratory specimens can provide valuable 86	
information to clinicians. 87	
 88	
We report here a study to evaluate the diagnostic accuracy of meningococcal LAMP as a 89	
near-patient test on respiratory (combined nasal and throat swab) and blood specimens in 90	
patients with suspected MD. Respiratory, blood and CSF specimens were tested in the 91	
laboratory using a reference PCR assay. Conventional blood and CSF culture methods were 92	
used, as per normal clinical practice, and the diagnostic performance of standard ‘non 93	
specific’ laboratory tests was evaluated for comparison.  94	
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Materials and methods 95	
 96	
Study design, inclusion criteria and specimens 97	
 98	
The study was approved by the Office for Research Ethics Committee Northern Ireland 99	
[reference 09/NIR02/43]. Clinical specimens were collected as per normal Royal Belfast 100	
Hospital for Sick Children (RBHSC) practice, with near-patient testing of aliquots as 101	
described below. Written informed consent was obtained from the parents of all study 102	
participants before their near-patient test results were included in the study. 103	
 104	
The study was designed as a prospective cohort study of diagnostic accuracy. Children (aged 105	
0 to 13 years) presenting to the emergency department between November 2009 and January 106	
2012 were eligible for inclusion. Patients with suspected meningitis or septicaemia entered 107	
a clinical care pathway and had a standard ‘meningococcal pack’ of investigations (Table 108	
1). This group included those whom the admitting doctor suspected might have MD: 109	
children with fever, unwell appearance, non-blanching rash, signs of meningitis or signs of 110	
septicaemia. 111	
 112	
Near-patient meningococcal ctrA LAMP 113	
 114	
Near-patient testing of clinical specimens (nasopharyngeal swabs and EDTA blood) was 115	
done in a room adjacent to the pediatric emergency department. Further details of the near-116	
patient LAMP protocol are given in the appendix. In brief, DNA was extracted from blood 117	
and respiratory (combined nasopharyngeal swab) specimens using a simple commercially 118	
available DNA extraction system. DNA extracts were analysed immediately using LAMP 119	
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reagents that were prepared in advance and stored frozen in the emergency department. 120	
Unlike molecular amplification methods such as PCR, positive LAMP reactions can be 121	
identified by visual inspection of the reaction tubes after incubation at an appropriate 122	
temperature. In this study, four near-patient LAMP tests were run for each patient (EDTA 123	
blood; combined nasopharyngeal swab; positive control; negative control) and test results 124	
were read after incubation at 63°C for 60 minutes. 125	
 126	
Reference laboratory tests 127	
 128	
Details of the gold standard reference laboratory tests are given in the appendix. 129	
 130	
Statistical methods  131	
 132	
Laboratory confirmed MD was defined as: “A clinically compatible case plus isolation of 133	
N. meningitidis or detection of N. meningitidis DNA from a normally sterile site (blood or 134	
CSF)”.15 Likelihood ratios (LR), sensitivity, specificity and positive and negative predictive 135	
values (PPV, NPV) were calculated for near-patient LAMP testing of nasopharyngeal 136	
specimens, blood specimens and both tests combined for diagnosis of MD. 95% confidence 137	
intervals were calculated for estimates of diagnostic accuracy. Staff in both the MRU and 138	
BHSCT laboratories were blinded to the results of near-patient testing.16  139	
 140	
Role of the funding source 141	
 142	
The funding sponsor had no role in the study design, data interpretation or decision to submit 143	
for publication. 144	
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 145	
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Results 147	
 148	
Laboratory confirmed meningococcal disease 149	
 150	
In total, 161 patients had a ‘meningococcal pack’ of investigations and were tested. 151	
Subsequently, one declined consent, and a further 12 were not approached for consent (two 152	
died; one child protection case; two discharged early; seven transferred to other units). The 153	
remaining 148 patients were consented into the study. Most were under five years old 154	
(median 11 months; range 17 days – 12.5 years) and 57% were male gender. 27/148 (18%) 155	
were found to have laboratory confirmed MD, and 121/148 (82%) had other conditions 156	
(Table 2). Only 7/27 (26%) of the children with confirmed MD had meningococcus isolated 157	
in blood culture, and only one of these was positive by blood culture alone. 26/27 (96%) 158	
were positive for meningococcal DNA in their blood by PCR. 8/27 (30%) of the children 159	
with confirmed MD had a lumbar puncture to obtain CSF (Table 3) and all were culture 160	
negative. Seven had CSF analysed for meningococcal DNA in the laboratory and 6/7 (86%) 161	
were positive. Antibiotics had been given prior to lumbar puncture to all patients in our 162	
study, giving CSF culture a sensitivity of zero. In contrast, molecular testing of CSF was 163	
clearly useful, although none of the patients here were positive by molecular testing of CSF 164	
alone. 165	
 166	
11 children with laboratory confirmed MD had viral co-infections diagnosed by routine 167	
molecular virology testing, and three were infected with more than one virus. One child was 168	
positive in blood for enterovirus, seven were positive for respiratory viruses (picornavirus, 169	
rhinovirus, enterovirus, influenza A, bocavirus) and three were positive in stool specimens 170	
(astrovirus, rotavirus or picornavirus). Four of the children who did not have MD had other 171	
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invasive bacterial infections confirmed by routine bacteriology testing. Two had S. 172	
pneumoniae in blood culture; one had E. coli in blood, urine and CSF culture; one had S. 173	
agalacticae in blood culture. 174	
 175	
Near-patient testing using meningococcal LAMP 176	
 177	
The median time taken to complete the near-patient meningococcal LAMP tests (from 178	
starting extraction to reading results) was 1 hour 26 minutes. Results of near-patient testing 179	
using meningococcal LAMP are shown in Table 4. 141/148 children had a combined nasal 180	
and throat swab taken and tested using the near-patient LAMP protocol. The performance 181	
of near-patient nasopharyngeal testing (Table 4A) was as follows: sensitivity 84% (95% CI 182	
65-94); specificity 100% (95% CI 98-100); PPV 100% (95% CI 81-100); NPV 97% (95% 183	
CI 91-99); positive LR ∞; negative LR 0.16 (95% CI 0.07-0.39). 144/148 children had 184	
sufficient blood taken for testing using the near-patient LAMP protocol. The performance 185	
of near-patient blood testing (Table 4B) was: sensitivity 84% (95% CI 72-99); specificity 186	
100% (95% CI 93-100); PPV 100% (95% CI 75-100); NPV 97% (95% CI 90-99); positive 187	
LR ∞; negative LR 0.16 (95% CI 0.01-0.42). All 148 children had at least one specimen 188	
(nasopharyngeal swab and/or blood) analysed in the near patient setting. If patients who 189	
were positive by either of the near-patient tests were considered to be positive, the combined 190	
performance of near-patient LAMP testing of blood and/or nasopharyngeal specimens 191	
(Table 4C) was: sensitivity 89% (95% CI 72-96); specificity 100% (95% CI 97-100); PPV 192	
100% (95% CI 83-100); NPV 98% (95% CI 93-99); positive LR ∞; negative LR 0.11 (95% 193	
CI 0.04-0.32). 194	
 195	
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Three patients with laboratory confirmed MD were negative by both near-patient LAMP 196	
tests. Two had classical signs and symptoms of MD, and the third was an atypical 197	
presentation; a two year-old girl recalled to the hospital when a blood culture taken the 198	
previous day grew N. meningitidis. At first presentation, her WCC and CRP were normal, 199	
and she was discharged on oral amoxicillin after a period of observation. When recalled 20 200	
hours later, her parents reported that she had remained well since discharge. Physical 201	
examination revealed no meningism, normal perfusion and a few non-blanching spots on 202	
her abdomen. Her WCC had risen to 28.2 x 109/l and CRP to 211 mg/l. Her nasopharyngeal 203	
and blood specimens were both PCR positive for meningococcal DNA. 204	
 205	
‘Non-specific’ laboratory tests 206	
 207	
The results of ‘non-specific’ laboratory tests are shown in Table 5. Near-patient LAMP 208	
testing was substantially more accurate than any of the routinely used non-specific tests for 209	
diagnosis of MD.  210	
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Discussion 211	
 212	
Compared to the gold standard laboratory diagnosis of MD, the near-patient LAMP assays 213	
gave impressive results. Comparison to WCC and CRP indicates that LAMP tests are more 214	
useful than conventional non-specific tests for both ruling in and ruling out meningococcal 215	
disease. In addition to being accurate, this study demonstrates that molecular testing in the 216	
emergency department is feasible. The LAMP assay performed similarly well in the near-217	
patient setting and the laboratory setting, using different extraction protocols and different 218	
operators, with results typically available in less than two hours. We describe the accuracy 219	
of meningococcal LAMP in terms of likelihood ratios, which are not affected by disease 220	
prevalence.17 Likelihood ratios greater than 10 and less than one are considered strong 221	
evidence for the value of a diagnostic test.18 By this metric, the near-patient LAMP assay 222	
used here is clearly useful for diagnosis of MD. 223	
 224	
There is likely to be resistance to testing of nasopharyngeal specimens for meningococcus 225	
because of the potential to detect asymptomatic carriage. No carriage was detected during 226	
this study. Although a larger study may have identified some carriage and reduced the 227	
specificity from 100%, the data supports our previous conclusion that molecular testing of 228	
nasopharyngeal specimens in very young children is diagnostically useful, and generally not 229	
confounded by carriage.14 A relatively non-invasive nasopharyngeal meningococcal LAMP 230	
test on children presenting with ‘fever without source’ where the prevalence of 231	
meningococcal disease is very low should perform with reasonable accuracy. In this context 232	
a positive result is strongly suggestive of disease and could prompt further investigation and 233	
treatment. Patients with a negative result could be discharged safely after a period of 234	
observation, subject to the universal advice to re-attend if deterioration occurs. Most children 235	
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with fever still present to their general practitioner where the prevalence of meningococcal 236	
disease is much lower still.19,20 A non-invasive test with a strong negative likelihood ratio 237	
used in combination with careful clinical assessment is likely to be even more valuable in 238	
this context. 239	
 240	
Our data support the cost minimisation analysis conducted by NICE which suggests that 241	
rapid (<24 hours) access to molecular (PCR) test results can reduce costs through earlier 242	
discharge of the relatively well patients. NICE conclude that “the infrastructure does not 243	
currently exist to support such a strategy and is unlikely to exist within the next few years”.13 244	
Meningococcal LAMP could be used immediately in any small to medium sized hospital 245	
with access to a basic laboratory to give results within a few hours. The meningococcal 246	
LAMP assay described here, used in combination with careful clinical assessment, could 247	
have led to earlier discharge of a significant number of ‘not unwell’ patients in this study 248	
who did not have MD. 249	
 250	
Many of the MD cases in this study also had viral co-infections. As reported previously21 251	
we note that in the absence of rapid molecular testing for bacterial pathogens, positive 252	
molecular virology test results for viruses such as enterovirus or picornavirus should not 253	
reassure clinicians that an unwell patient does not have MD.  254	
 255	
One limitation of our study was that the proportion of positive cases (19%) was lower than 256	
a previous study in our unit (33%) although this confirms there was no bias towards more 257	
severe case. The blood culture positive rate of ~25% is similar to previous studies22,23 and 258	
the ‘PCR only’ case ascertainment (77%) is slightly higher than reports from the national 259	
reference laboratory23 indicating a representative case mix of patients. We experienced 260	
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historically low levels of meningococcal disease during this study, with only 36 confirmed 261	
cases in Northern Ireland in 2011 compared with 94 cases in 2004. This has resulted in wider 262	
confidence intervals for our estimates of diagnostic accuracy. A small number of discordant 263	
test results were seen, which illustrates the problems that are common with definitive 264	
diagnosis of MD, even using the best available reference laboratory tests. This study was 265	
not designed to investigate whether early availability of definitive test results could influence 266	
patient management and improve clinical outcomes. A larger multi-centre trial of near-267	
patient LAMP for children presenting with ‘fever without source’ could address this 268	
important question. Since this work was completed, the meningococcal LAMP test has been 269	
developed further, using freeze-dried reagents, real-time detection and improved 270	
amplification chemistry to improve sensitivity and reduce the assay time to below 20 271	
minutes. 272	
 273	
This study is the first to evaluate a rapid near-patient molecular diagnostic test for MD, and 274	
also the first demonstration of near-patient testing using LAMP in a UK hospital. The data 275	
support our initial hypothesis that testing of nasal and throat swabs using meningococcal 276	
LAMP in a near-patient setting is useful as a rapid diagnostic test for N. meningitidis. LAMP 277	
testing of nasopharyngeal or blood specimens in a near-patient setting was both feasible and 278	
accurate, and combining the results for both specimen types further increased the diagnostic 279	
accuracy. These data suggest the ability to rapidly detect a pathogenic (capsular) strain of N. 280	
meningitidis in the nasopharynx of a febrile child whose parents are sufficiently concerned 281	
to seek medical advice can give clinically useful information. Current advice from Public 282	
Health England (PHE) and NICE on testing of respiratory specimens is inconsistent. PHE 283	
recommends culture of nasopharyngeal swabs from suspected cases.24 In contrast, NICE 284	
explicitly recommend that nasopharyngeal specimens are not tested, by any method.13 The 285	
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potential to diagnose and treat life-threatening invasive disease early outweighs the small 286	
risk of detecting asymptomatic carriage in young children, and this should be considered in 287	
reviewed NICE guidance. 288	
 289	
Research in context panel 290	
 291	
Systematic review 292	
 293	
A PubMed search on Dec 5th, 2014, with the terms ((near patient AND meningococc*) OR 294	
(near patient AND meningitidis)) found 16 papers, none related to near-patient testing. 295	
Searching with the terms ((point of care AND meningococc*) OR (point of care AND 296	
meningitidis)) found 7 papers, two reporting methods suitable for near-patient testing8,25. 297	
One of these25 describes a LAMP-based testing system that "has potential" for point of care 298	
testing, but presents no clinical validation data in either laboratory or near-patient settings. 299	
The other8 is the assay used here, and is the first published and clinically validated LAMP 300	
assay for rapid detection of meningococcal DNA. This study is the first to evaluate such an 301	
assay for near-patient testing.  302	
 303	
Interpretation 304	
 305	
There is currently no effective diagnostic test for meningococcal disease2. Cases with clear 306	
signs and symptoms are (or should be) diagnosed clinically, and laboratory testing serves 307	
mainly to confirm the clinical diagnosis. The decision to obtain and test sterile site 308	
specimens (blood or CSF) presumes that a clinical suspicion of serious invasive disease 309	
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already exists. No clinician who suspects meningococcal disease will wait for laboratory 310	
results before starting antibiotic treatment, so testing simply confirms an existing diagnosis. 311	
 312	
Unfortunately, in the absence of definitive diagnostic testing, children with non-specific 313	
symptoms who are actually in the early stages of meningococcal disease are frequently 314	
overlooked. Half of children with confirmed meningococcal infection have been seen by a 315	
healthcare professional and either falsely reassured or discharged in the hours leading up to 316	
their clinical diagnosis and treatment.3 It seems self-evident that identifying and treating 317	
these children earlier could improve clinical outcomes, although there is no data to confirm 318	
this. Without an accurate diagnostic test for meningococcal disease, ideally delivered at 319	
point-of-care, there is little prospect of identifying these cases earlier in a clinical trial. 320	
 321	
This study confirms that molecular testing using LAMP to detect meningococcus is highly 322	
sensitive and specific, and demonstrates this for the first time in the context of near-patient 323	
testing in the emergency department. Molecular tests to detect this pathogen should not be 324	
confined to the reference laboratory. 325	
 326	
 327	
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TABLE 1 'Meningococcal pack' investigations 
Specimen Volume Test 
Whole blood At least 1ml Blood culture, collected prior to antibiotic therapy if possible 
EDTA blood 1ml Meningococcal ctrA TaqMan® qPCR 
EDTA blood 1mla Enterovirus / picornavirus RT-qPCR 
EDTA blood 0.5ml Full blood count 
Clotted blood 0.5ml Routine biochemistry: renal function; electrolytes; calcium; 
magnesium; C-reactive protein (CRP) 
Heparinised blood 1.4ml Coagulation screen 
EDTA blood 2ml Routine haematology / blood group 
Combined nasal & 
throat swab 
1mla Swabs combined in eNAT transport medium; meningococcal 
ctrA TaqMan® qPCR / LAMP and viral screen 
   
CSF (optional) 1mlb Routine biochemistry, WCC, culture and viral screen 
a0.2ml aliquots of these specimens were processed using the near-patient LAMP protocol. 
bLumbar puncture to obtain CSF is done only if clinically indicated. 
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TABLE 2 Reference laboratory results for confirmed MD cases (n=27) 
 Reference tests to confirm MD  Laboratory LAMP tests 
Patient no. Blood culture Blood PCRa Serogroupa Swab LAMPb Blood LAMP 
3 + + B + + 
4 - + B + + 
10 - + B + + 
13 - + B + + 
21 - + B + NA 
29 + + B - + 
30 - + B + + 
36 - + B + + 
73 - + B + + 
85 + + Y + + 
87 - + B + + 
91 + + B + + 
93 - + B + + 
94 - + B + + 
106 - + B + + 
110 - + B + + 
114 + + B + + 
116 - + B + + 
132 - + B + + 
133 - + B + + 
134 - + B + + 
135 - + B NA + 
145 - + B + + 
146 + + B + + 
157 - + B + + 
158 - + B + + 
160 + + B NA + 
a PCR testing (ctrA TaqMan® assay and specific meningococcal serogrouping qPCR 
assays) were performed in Manchester (MRU), Belfast (BHSCT) or both. 
b Combined nasopharyngeal swab; NA = specimen not available  
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TABLE 3 Results for patients with confirmed meningococcal disease where CSF was 
examined 
Patient no. Time from 
treatment (hrs) 
CSF culture CSF LAMP CSF TaqMan 
10 22 - + + 
13 126 - - - 
36 46 - + + 
73 16 - + ND 
94 42 - + + 
114 2 - + + 
145 48 - + + 
158 44 - ND ND 
ND, not done 
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TABLE 4 Results of near-patient meningococcal LAMP testing 
A: Nasopharyngeal specimens (n=141)     
 Meningococcal disease 
Positive Negative 
Nasopharyngeal 
LAMP 
Positive 21 0 
Negative 4 116 
 
B: EDTA blood specimens (n=144)      
 Meningococcal disease 
Positive Negative 
Blood 
LAMP 
Positive 22 0 
Negative 4 118 
 
C: Combined results for both specimen types (n=148)   
  Meningococcal disease 
Nasopharyngeal 
&/or blood  
LAMP 
 Positive Negative 
Positive 24 0 
Negative 3 121 
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TABLE 5 Results of ‘non-specific’ laboratory tests 
Testa  Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Positive LR 
(95% CI) 
Negative LR 
(95% CI) 
CRP >10 mg/l  93% 
(77 to 98) 
64% 
(55 to 72) 
2.60 
(1.99 - 3.39) 
0.11 
(0.03 - 0.44) 
CRP >60 mg/l  63% 
(44 to 78) 
91% 
(85 to 95) 
7.43 
(3.84 - 14.37) 
0.41 
(0.25 - 0.66) 
Abnormal  
WCC  
78% 
(59 to 89) 
65% 
(56 to 73) 
2.22 
(1.61 - 3.05) 
0.34 
(0.17 - 0.70) 
Abnormal  
neutrophils 
85% 
(67 to 94) 
52% 
(43 to 61) 
1.78 
(1.39 - 2.28) 
0.28 
(0.11 - 0.71) 
aCRP cutoffs used in the literature range from 8 to 100 (reviewed by NICE13). Cutoffs used 
here were selected to optimise sensitivity (10 mg/l) or specificity (60 mg/l) based on ROC 
analysis (data not shown). The reference normal range for WCC in our laboratory is 5 to 
13 x 109/l. 
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Supplementary material 
 
Near-patient meningococcal LAMP protocol 
 
DNA was extracted from EDTA blood (200μl) and eNat medium (200μl, containing 
combined nasal and throat swabs) using a QuickGene Mini80 system and DB-S DNA kit 
(Fuji Corporation, Tokyo, Japan). DNA extracts (100μl) were denatured (95°C, 5 minutes) 
cooled on ice and tested immediately. Each LAMP reaction (25μl) comprised 20μl of LAMP 
mastermix and 5μl of DNA extract in a 100μl PCR tube (Abgene Ltd., Epsom, UK). A base 
LAMP mastermix containing all reagents except DNA polymerase (Bst2.0, 8U/μl; New 
England Biolabs, Ipswich, USA) and Fluorescence Detection Reagent (FDR; Eiken 
Chemical Company, Japan) was stored at -20°C in 90μl aliquots prior to use. Components 
of the base mastermix (buffer, LAMP primers, betaine, MgSO4 and dNTPs) were as 
described previously.1 For each patient, a 90μl aliquot of mastermix was thawed, mixed with 
DNA polymerase (5μl) and FDR (5μl) and used immediately. Reactions were incubated at 
63°C using a standard thermal cycler (GeneAmp 9700, Life Technologies, Paisley, UK). 
After 60 minutes, tubes were visually inspected for a colour change from pale orange to 
bright yellow/green to identify positive reactions, as illustrated in Figure S1. 
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Figure S1. Negative (A) and positive (B) meningococcal LAMP reaction tubes. 
 
Reference laboratory testing 
 
Blood and CSF specimens were cultured according to UK standard methods2,3 using an 
automated BacT/ALERT® 3D Microbial Detection System with BacT/ALERT® FA culture 
medium (bioMérieux, Marcy l’Etoile, France). Isolates were identified using the VITEK® 2 
system (bioMérieux) and latex bead agglutination tests (Pastorex Meningitis Kit, Bio-Rad 
Laboratories Ltd., Hemel Hempstead, UK). PCR testing of EDTA blood was performed by 
the MRU or the Belfast laboratory or both. In Belfast, EDTA blood specimens (200μl) were 
extracted using the QIAsymphony SP automated extraction system and DSP Virus/Pathogen 
Mini Kit / Complex 200 protocol (Qiagen Ltd., Crawley, UK). PCR assays (10μl) to detect 
the meningococcal ctrA gene used Invitrogen Platinum® Quantitative PCR SuperMix-UDG 
(Life Technologies Ltd., Paisley, UK) with primers and a TaqMan® probe as described 
A B
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previously.4 An additional reverse primer (5'-TTGCCGCGGATTGGCCACCA-3') was 
used5 to ensure that strains with known mutations in the ctrA gene could be reliably 
detected.6,7 PCR assays were run on a LightCycler® 480II real-time PCR system (Roche 
Diagnostics Ltd., Burgess Hill, UK) using the following thermal cycling protocol: 50°C (10 
minutes); 95°C (2 minutes); 45 cycles of 95°C (15 seconds) and 60°C (30 seconds). CSF 
specimens (200μl) were tested in the Belfast laboratory using either PCR or LAMP, as per 
the near-patient testing protocol, except that DNA extracts were prepared using a QIAamp 
DNA Blood Mini Kit (Qiagen Ltd.). 
 
Serogrouping PCR 
  
A commercially available real-time PCR kit (Diagenode Diagnostics, Léige, Belgium) was 
used to determine the genetic capsule type for confirmed cases, with specific primers and 
TaqMan® probes for capsule biosynthesis genes of the five serogroups (A, B, C, W135, Y) 
most frequently associated with MD. Reactions (10 µl) contained 1X Platinum® 
Quantitative PCR SuperMix-UDG (Invitrogen Ltd, Paisley, UK), 4 mM MgCl2, 1 µl of 
primer and probe mix, 0.2 mg/ml bovine serum albumin (Sigma-Aldrich Ltd., Dorset, UK), 
nuclease free water and 2 µl of template DNA. Assays were run on a LightCycler® 480II 
real-time PCR system using the manufacturer’s recommended cycling protocol: 50°C (2 
minutes); 95°C for (10 minutes); 45 cycles of 95°C (10 seconds), 60°C (40 seconds) and 
72°C (1 second). 
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